5-MeO-DiBF is a psychedelic substance that has been available for purchase online as a designer drug. It gained recognition in December 2015 when a forensic laboratory in Slovenia conclusively identified it. This compound is believed to function as an agonist for the serotonin receptors within the 5-HT1A and 5-HT2 families.

Structurally, it shares a resemblance with the psychedelic tryptamine derivative 5-MeO-DiPT. However, a significant distinction lies in the replacement of the indole nitrogen atom with oxygen, resulting in 5-MeO-DiBF being classified as a benzofuran derivative. In terms of potency as a serotonin agonist, it is notably less potent than 5-MeO-DiPT. Nonetheless, it exhibits relatively greater activity at 5-HT1A receptors while still predominantly affecting the 5-HT2 family of serotonin receptors.

IUPAC name
CAS Numbernone
PubChem CID125276632
Chemical and physical data
Molar mass275.392 g·mol−1

Legal status

The 1971 Convention on Psychotropic Substances does not currently regulate 5-MeO-DiBF. Consequently, it falls into a legal ambiguity in many countries. However, selling it for human consumption might lead to legal consequences under stringent analog acts.


1. What is 5-MeO-DiBF?

  • 5-MeO-DiBF is a psychedelic substance that has gained attention as a designer drug. It is chemically related to other psychoactive compounds.

2. Is 5-MeO-DiBF legal?

  • The legal status of 5-MeO-DiBF varies by country and jurisdiction. It is not regulated under the 1971 Convention on Psychotropic Substances, creating a legal gray area in many places. However, selling it for human consumption can lead to legal consequences under analog drug laws in some regions.

3. How does 5-MeO-DiBF compare to other psychedelics?

  • 5-MeO-DiBF shares structural similarities with other psychedelic compounds, but it has its unique effects and characteristics. Its potency and receptor affinities may differ from other substances.

4. What are the potential effects of 5-MeO-DiBF?

  • 5-MeO-DiBF is known for its psychedelic effects, which may include altered perception, changes in consciousness, and hallucinations. However, the specific experiences can vary among individuals.

5. Is 5-MeO-DiBF safe to use?

  • The safety and long-term effects of 5-MeO-DiBF are not well-documented. As with any psychoactive substance, responsible and cautious use is crucial, particularly when using a compound with limited research.

6. Are there any risks associated with 5-MeO-DiBF use?

  • Using 5-MeO-DiBF, like other psychedelics, carries potential risks, including psychological distress, anxiety, and other adverse effects. It’s essential to consider set and setting when using this substance.

7. How is 5-MeO-DiBF typically consumed?

  • 5-MeO-DiBF can be ingested through various methods, including oral consumption or vaporization, depending on the form in which it is available.

8. Can 5-MeO-DiBF be used for therapeutic purposes?

  • There is limited research on the therapeutic potential of 5-MeO-DiBF, and it is not approved for medical or therapeutic use. Other psychedelics, like psilocybin and MDMA, have been more extensively studied for therapeutic applications.

9. Is 5-MeO-DiBF addictive?

  • The addictive potential of 5-MeO-DiBF is not well understood, but it is generally considered to have a lower risk of physical dependence compared to substances like opioids or stimulants. However, psychological dependence can still occur.

10. Where can I find more information about 5-MeO-DiBF?

  • Given the evolving legal and scientific landscape surrounding 5-MeO-DiBF, it’s important to consult reliable sources of scientific literature and seek advice from healthcare professionals. Staying informed and making well-informed decisions is crucial when considering the use of this substance.


  1. In the Microgram Journal, Casale JF and Hays PA published a study titled “The Characterization of 2-(5-Methoxy-1-benzofuran-3-yl)-N,N-dimethylethanamine (5-MeO-BFE) and Differentiation from its N-Ethyl Analog.” This research, found in Volume 9, Issue 1, spans pages 39 to 45.
  2. “Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA” is available from the European Monitoring Center for Drugs and Drug Addiction in a downloadable PDF format. It provides insights into drug-related activities and enforcement in the year 2015.
  3. In May 1992, Tomaszewski Z, Johnson MP, Huang X, and Nichols DE published a study titled “Benzofuran bioisosteres of hallucinogenic tryptamines” in the Journal of Medicinal Chemistry (Volume 35, Issue 11, Pages 2061-2064). This research explores compounds related to hallucinogenic tryptamines and their structural similarities.
  4. McKenna DJ, Repke DB, Lo L, and Peroutka SJ conducted research in March 1990 titled “Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes.” This study, published in Neuropharmacology (Volume 29, Issue 3, Pages 193-198), delves into the interactions of indolealkylamines with various serotonin receptor subtypes.

Leave a Comment

Your email address will not be published. Required fields are marked *